Skip to Content

Mr. Pejic is a co-chair of the Greenblum & Bernstein litigation/trial practice group, and is a member of the firm’s start-up/acquisition group.  Prior to joining G&B in 1999, Mr. Pejic clerked for a U.S. District Court Judge, and completed a mini-pupilage at Grey’s Inn, London, England.  Mr. Pejic litigates a wide spectrum of technologies on behalf of numerous foreign companies in disputes before the U.S. Federal District and Appellate Courts and in contested proceedings before the U.S. Patent and Trademark Office, advises in merger/acquisition transactions, and counsels clients on intellectual property matters including patent, licensing and monetization strategies.  Mr. Pejic speaks on and has published articles on these issues as well U.S. litigation practice and strategies, and currently serves as the Secretary of the U.S. FICPI section.    

Mr. Pejic’s primary focus is pharmaceutical/bio-tech, including Hatch-Waxman ANDA litigations, and high-tech technologies.  He has represented both innovator and generic drug companies in litigations, including serving as lead trial and appellate counsel for generic manufacturers in several “blockbuster” drug litigations, as well as patentees and accused infringers in various other technologies, including medical devices.  Mr. Pejic additionally has served as lead IP counsel in due diligence and negotiations for multiple transactions to acquire/sell patents, business divisions and products as well in/out licensing of patent portfolios in the pharma/bio fields.  Mr. Pejic holds a B.S. in Chemical Engineering, a Juris Doctorate and an LL.M. in International and Comparative Law with a focus on Intellectual Property from Georgetown Law Center.


  • Lead trial counsel in several blockbuster drug trials
  • Lead appellate counsel is several appeals to the Court of Appeals for the Federal Circuit
  • Lead intellectual property counsel in transactions totaling in the hundreds of millions of dollars
  • Executive committee of International Federation of Intellectual Property Attorneys (FICPI) (2013-present)
  • Travels extensively throughout Europe


  • Law Clerk, Hon. H. Dale Cook, U.S. District for the Northern District of Oklahoma – 1997-1998
  • Partner Greenblum & Bernstein, P.L.C. – 2006-2009
  • Equity Partner Greenblum & Bernstein, P.L.C. – 2009-Present

Offices/Professional Activities

  • U.S. Council Member International Federation of Intellectual Property Attorneys (FICIP) (2013-present)
  • Certified Patent Valuation Analyst Faculty Member (2011-Present)
  • Licensing Executive Society (2010-Present, Sector Liaison – Publications)
  • Licensing Executive Society (2010-Present, Sector Liaison – Communications)
  • Generic Pharmaceutical Association (2004-Present, Membership Committee)
  • University of Arkansas Vice Chancellor’s Advisory Counsel (2007-Present, Board Member and Chairman 2008-09)

Professional Associations and Memberships

  • American Bar Association
  • American Intellectual Property Law Association
  • Generic Pharmaceutical Association (Membership Committee) 
  • International Federation of Intellectual Property Attorneys
  • International Association for the Protection of Intellectual Property
  • Licensing Executive Society
  • PTAB Bar Association

Representative Publications

  • Bernstein, B., Fink M., Pejic P.B. ABA “Licensing U.S. Jurisdiction.” Getting The Deal Through – in print and on-line, Law Business Research Ltd. (2011-21 editions)
  • Pejic P.B., “On Litigating Hatch-Waxman Patent Infringement Cases in the Eastern District of Virginia” Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector April 2014 11(1-2) 74-77
  • Pejic P.B., “Recent Federal Circuit rulings strengthen obviousness-type double patenting defense to assertions of patent infringement in pharmaceutical litigations.” Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector April 2011 8: 111-116
  • Greenblum, N., Fink, M., Roylance, S., Pejic, P.B., Myers-Payne, S.C., Braier, P. “Generic Drugs in a Changing Intellectual Property Landscape.” The Pharmaceutical Regulatory Process, Second Edition, pp. 143-180, Ira R. Berry and Robert P. Martin, eds., Informa Health Care (2008)